

Emmanuel Stip

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8550142/publications.pdf>

Version: 2024-02-01

123
papers

2,815
citations

186265

28
h-index

233421

45
g-index

143
all docs

143
docs citations

143
times ranked

4056
citing authors

#	ARTICLE	IF	CITATIONS
1	Clozapine Alone versus Clozapine and Risperidone with Refractory Schizophrenia. <i>New England Journal of Medicine</i> , 2006, 354, 472-482.	27.0	249
2	Contradictory cognitive capacities among substance-abusing patients with schizophrenia: A meta-analysis. <i>Schizophrenia Research</i> , 2008, 100, 242-251.	2.0	128
3	Internet Addiction, Hikikomori Syndrome, and the Prodromal Phase of Psychosis. <i>Frontiers in Psychiatry</i> , 2016, 7, 6.	2.6	76
4	On the trail of a cognitive enhancer for the treatment of schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 219-232.	4.8	74
5	The Incidence and Nature of Cerebellar Findings in Schizophrenia: A Quantitative Review of fMRI Literature. <i>Schizophrenia Bulletin</i> , 2013, 39, 797-806.	4.3	71
6	Psychotic Symptoms as a Continuum between Normality and Pathology. <i>Canadian Journal of Psychiatry</i> , 2009, 54, 140-151.	1.9	69
7	Brain activity during emotionally negative pictures in schizophrenia with and without flat affect: An fMRI study. <i>Psychiatry Research - Neuroimaging</i> , 2005, 140, 1-15.	1.8	68
8	Pain perception in schizophrenia: No changes in diffuse noxious inhibitory controls (DNIC) but a lack of pain sensitization. <i>Journal of Psychiatric Research</i> , 2008, 42, 1010-1016.	3.1	67
9	Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review. <i>Schizophrenia Research and Treatment</i> , 2012, 2012, 1-12.	1.5	67
10	The psychological impact of the COVID-19 pandemic on adults and children in the United Arab Emirates: a nationwide cross-sectional study. <i>BMC Psychiatry</i> , 2021, 21, 224.	2.6	66
11	CANTAB explicit memory is less impaired in addicted schizophrenia patients. <i>Brain and Cognition</i> , 2005, 59, 38-42.	1.8	63
12	Disaster management of the psychological impact of the COVID-19 pandemic. <i>International Journal of Emergency Medicine</i> , 2021, 14, 19.	1.6	55
13	Cognitive discernible factors between schizophrenia and schizoaffective disorder. <i>Brain and Cognition</i> , 2005, 59, 292-295.	1.8	54
14	Understanding access and use of technology among youth with first-episode psychosis to inform the development of technology-enabled therapeutic interventions. <i>Microbial Biotechnology</i> , 2017, 11, 72-76.	1.7	52
15	Restoration of frontal activation during a treatment with quetiapine: an fMRI study of blunted affect in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 21-26.	4.8	46
16	Pain Perception in Schizophrenia: Evidence of a Specific Pain Response Profile. <i>Pain Medicine</i> , 2012, 13, 1571-1579.	1.9	44
17	Impact of the resolution of brain parcels on connectome-wide association studies in fMRI. <i>NeuroImage</i> , 2015, 123, 212-228.	4.2	44
18	Multisite generalizability of schizophrenia diagnosis classification based on functional brain connectivity. <i>Schizophrenia Research</i> , 2018, 192, 167-171.	2.0	43

#	ARTICLE	IF	CITATIONS
19	Antipsychotic-induced changes in blood levels of leptin in schizophrenia: a meta-analysis. <i>Canadian Journal of Psychiatry</i> , 2015, 60, S26-34.	1.9	42
20	Sensation-seeking, social anhedonia, and impulsivity in substance use disorder patients with and without schizophrenia and in non-abusing schizophrenia patients. <i>Psychiatry Research</i> , 2012, 200, 237-241.	3.3	40
21	Meta-Analysis of Depressive Symptoms in Dual-Diagnosis Schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2007, 41, 792-799.	2.3	39
22	Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders. <i>International Clinical Psychopharmacology</i> , 2011, 26, 183-192.	1.7	39
23	Mutations associated with neuropsychiatric conditions delineate functional brain connectivity dimensions contributing to autism and schizophrenia. <i>Nature Communications</i> , 2020, 11, 5272.	12.8	35
24	Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naïve patients with psychotic disorders. <i>Schizophrenia Research</i> , 2005, 80, 131-133.	2.0	31
25	A Study of Theory of Mind in Paranoid Schizophrenia: A Theory or Many Theories?. <i>Frontiers in Psychology</i> , 2012, 3, 432.	2.1	31
26	Effects of high intensity interval training among overweight individuals with psychotic disorders: A randomized controlled trial. <i>Schizophrenia Research</i> , 2019, 210, 278-286.	2.0	31
27	Procedural Learning in Schizophrenia Can Reflect the Pharmacologic Properties of the Antipsychotic Treatments. <i>Cognitive and Behavioral Neurology</i> , 2004, 17, 32-40.	0.9	30
28	Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: a randomized placebo-controlled trial. <i>Addiction</i> , 2021, 116, 2431-2442.	3.3	30
29	The Large Action of Chlorpromazine: Translational and Transdisciplinary Considerations in the Face of COVID-19. <i>Frontiers in Pharmacology</i> , 2020, 11, 577678.	3.5	29
30	Neural Correlates of Sad Feelings in Schizophrenia with and without Blunted Affect. <i>Canadian Journal of Psychiatry</i> , 2005, 50, 909-917.	1.9	28
31	Comparing Tolerability of Olanzapine in Schizophrenia and Affective Disorders. <i>Drug Safety</i> , 2012, 35, 819-836.	3.2	28
32	Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec. <i>Therapeutic Advances in Psychopharmacology</i> , 2018, 8, 287-301.	2.7	28
33	Differential Effects of D2- and D4-Blocking Neuroleptics on the Procedural Learning of Schizophrenic Patients. <i>Canadian Journal of Psychiatry</i> , 1996, 41, S21-S24.	1.9	27
34	Endocannabinoids and Schizophrenia. <i>Pharmaceuticals</i> , 2010, 3, 3101-3126.	3.8	27
35	Neural correlates of emotional recognition memory in schizophrenia: Effects of valence and arousal. <i>Psychiatry Research - Neuroimaging</i> , 2011, 194, 245-256.	1.8	27
36	Who pioneered the use of antipsychotics in North America?. <i>Canadian Journal of Psychiatry</i> , 2015, 60, S5-13.	1.9	27

#	ARTICLE	IF	CITATIONS
37	Sex Differences in the Cerebral Function Associated with Processing Of Aversive Stimuli by Schizophrenia Patients. Australian and New Zealand Journal of Psychiatry, 2007, 41, 136-141.	2.3	26
38	ERP investigation of study-test background mismatch during face recognition in schizophrenia. Schizophrenia Research, 2012, 134, 101-109.	2.0	26
39	A randomized controlled trial with a Canadian electronic pill dispenser used to measure and improve medication adherence in patients with schizophrenia. Frontiers in Pharmacology, 2013, 4, 100.	3.5	26
40	Genealogy of instruments for prodrome evaluation of psychosis. Frontiers in Psychiatry, 2013, 4, 25.	2.6	25
41	Long-acting antipsychotic medication as first-line treatment of first-episode psychosis with comorbid substance use disorder. Microbial Biotechnology, 2020, 14, 69-79.	1.7	24
42	Sex differences in memory processing in schizophrenia: An event-related potential (ERP) study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 1-10.	4.8	23
43	Clozapine and visuospatial processing in treatment-resistant schizophrenia. Cognitive Neuropsychiatry, 2013, 18, 615-630.	1.3	23
44	Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis. Expert Opinion on Drug Safety, 2012, 11, 713-732.	2.4	20
45	Increased ventro-medial prefrontal activations in schizophrenia smokers during cigarette cravings. Schizophrenia Research, 2016, 173, 30-36.	2.0	20
46	Plasma Endocannabinoid Alterations in Individuals with Substance Use Disorder are Dependent on the "Mirror Effect" of Schizophrenia. Frontiers in Psychiatry, 2012, 3, 85.	2.6	19
47	Emotion processing in treatment-resistant schizophrenia patients treated with clozapine: An fMRI study. Schizophrenia Research, 2015, 168, 377-380.	2.0	18
48	An Exploratory, Open-Label, Randomized Trial Comparing Risperidone Long-Acting Injectable with Oral Antipsychotic Medication in the Treatment of Early Psychosis. Clinical Schizophrenia and Related Psychoses, 2016, 9, 198-208.	1.4	18
49	Altered brain connectivity in patients with schizophrenia is consistent across cognitive contexts. Journal of Psychiatry and Neuroscience, 2017, 42, 17-26.	2.4	17
50	A microstructural study of sleep instability in drug-naive patients with schizophrenia and healthy controls: Sleep spindles, rapid eye movements, and muscle atonia. Schizophrenia Research, 2014, 155, 31-38.	2.0	16
51	La conscience des déficits neurocognitifs dans la schizophrénie: une méta-analyse. Sante Mentale Au Quebec, 0, 39, 183-200.	0.1	15
52	Running for your life: A review of physical activity and cardiovascular disease risk reduction in individuals with schizophrenia. Journal of Sports Sciences, 2016, 34, 1500-1515.	2.0	15
53	Catatonia with schizophrenia: From ECT to rTMS. L'Encephale, 2018, 44, 183-187.	0.9	15
54	Psychiatry and COVID-19: The Role of Chlorpromazine. Canadian Journal of Psychiatry, 2020, 65, 739-740.	1.9	15

#	ARTICLE	IF	CITATIONS
55	Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis. <i>International Clinical Psychopharmacology</i> , 2020, 35, 221-228.	1.7	15
56	The Impact of the COVID-19 "Infodemic" on Well-Being: A Cross-Sectional Study. <i>Journal of Multidisciplinary Healthcare</i> , 2022, Volume 15, 289-307.	2.7	15
57	Intrusion errors in explicit memory: Their differential relationship with clinical and social outcome in chronic schizophrenia. <i>Cognitive Neuropsychiatry</i> , 2007, 12, 112-127.	1.3	14
58	Ziprasidone for Psychotic Disorders: A Meta-Analysis and Systematic Review of the Relationship Between Pharmacokinetics, Pharmacodynamics, and Clinical Profile. <i>Clinical Therapeutics</i> , 2011, 33, 1853-1867.	2.5	14
59	Cannabis abuse is associated with better emotional memory in schizophrenia: A functional magnetic resonance imaging study. <i>Psychiatry Research - Neuroimaging</i> , 2013, 214, 24-32.	1.8	14
60	Impact of switching to long-acting injectable antipsychotics on health services use in the treatment of schizophrenia. <i>Canadian Journal of Psychiatry</i> , 2015, 60, S40-7.	1.9	14
61	Long-Term Metabolic Effects in French-Canadian Children and Adolescents Treated with Second-Generation Antipsychotics in Monotherapy or Polytherapy: A 24-Month Descriptive Retrospective Study. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 827-836.	1.9	13
62	The screen for cognitive impairment in psychiatry (SCIP) is associated with disease severity and cognitive complaints in major depression. <i>International Journal of Psychiatry in Clinical Practice</i> , 2019, 23, 49-56.	2.4	13
63	Switching atypical antipsychotics: a review. <i>Acta Neuropsychiatrica</i> , 2004, 16, 301-313.	2.1	12
64	Fatal agranulocytosis: The use of olanzapine in a patient with schizophrenia and myelodysplasia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 297-300.	4.8	12
65	Les RaeRae et Mahu: troisième sexe polynésien. <i>Sante Mentale Au Quebec</i> , 0, 40, 193-208.	0.1	12
66	Antipsychotic-induced parkinsonism is associated with working memory deficits in schizophrenia-spectrum disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 147-154.	3.2	12
67	Reward-related decision-making in schizophrenia: A multimodal neuroimaging study. <i>Psychiatry Research - Neuroimaging</i> , 2019, 286, 45-52.	1.8	12
68	The Neural Correlates of Mental Rotation Abilities in Cannabis-Abusing Patients with Schizophrenia: An fMRI Study. <i>Schizophrenia Research and Treatment</i> , 2013, 2013, 1-10.	1.5	11
69	Suicidal Ideation and Schizophrenia: Contribution of Appraisal, Stigmatization, and Cognition. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 726-734.	1.9	11
70	Saliency network and olanzapine in schizophrenia: implications for treatment in anorexia nervosa. <i>Canadian Journal of Psychiatry</i> , 2015, 60, S35-9.	1.9	11
71	Antipsychotic utilization trajectories three years after initiating or reinitiating treatment of schizophrenia: A state sequence analysis approach. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 469-480.	4.5	11
72	Sexual dimorphism of spatial working memory profiles in schizophrenia. <i>Cognitive Neuropsychiatry</i> , 2010, 15, 397-405.	1.3	10

#	ARTICLE	IF	CITATIONS
73	Relationship Between Insight into Cognition, Extrapyramidal Symptoms and Mental Illness in Schizophrenia. Australian and New Zealand Journal of Psychiatry, 2011, 45, 596-597.	2.3	10
74	Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic. Asian Journal of Psychiatry, 2020, 54, 102203.	2.0	10
75	Daily Task Performance and Information Processing among People with Schizophrenia and Healthy Controls: A Comparative Study. British Journal of Occupational Therapy, 2014, 77, 466-474.	0.9	9
76	Three-Year Naturalistic Study On Early Use Of Long-Acting Injectable Antipsychotics In First Episode Psychosis. Psychopharmacology Bulletin, 2018, 48, 25-61.	0.0	9
77	Cognitive function and depression in symptom resolution in schizophrenia patients treated with an atypical antipsychotic. Brain and Cognition, 2004, 55, 463-465.	1.8	8
78	Evidence from paranoid schizophrenia for more than one component of theory of mind. Frontiers in Psychology, 2015, 6, 1643.	2.1	8
79	Bibliotherapy: Reading OVID During COVID. Frontiers in Psychiatry, 2020, 11, 567539.	2.6	8
80	People with mental illness should be included in COVID-19 vaccination. Lancet Psychiatry, the, 2021, 8, 275-276.	7.4	8
81	Association between previous and future antipsychotic adherence in patients initiating clozapine: real-world observational study. British Journal of Psychiatry, 2022, 220, 347-354.	2.8	8
82	Glycine and D-serine improve the negative symptoms of schizophrenia. Evidence-Based Mental Health, 2005, 8, 82-82.	4.5	7
83	Antibiotic-associated encephalopathy Author Response. Neurology, 2016, 87, 1188-1189.	1.1	7
84	First clinical use of epidural stimulation in catatonia. Brain Stimulation, 2017, 10, 859-861.	1.6	7
85	Exploring cannabidiol effects on inflammatory markers in individuals with cocaine use disorder: a randomized controlled trial. Neuropsychopharmacology, 2021, 46, 2101-2111.	5.4	7
86	Cannabidiol effects on cognition in individuals with cocaine use disorder: Exploratory results from a randomized controlled trial. Pharmacology Biochemistry and Behavior, 2022, 216, 173376.	2.9	7
87	Multidimensional analysis of adult patients's care trajectories before a first diagnosis of schizophrenia. NPJ Schizophrenia, 2022, 8, .	3.6	7
88	Predictors of Community Functioning in Schizophrenia and Substance Use Disorder Patients. Community Mental Health Journal, 2013, 49, 317-322.	2.0	6
89	Redevelopment of tertiary psychiatric services in British Columbia: A prospective study of clinical, social, and residential outcomes of former long-stay inpatients. Schizophrenia Research, 2013, 149, 96-103.	2.0	6
90	Efficacy of onabotulinumtoxinA in the treatment of unipolar major depression: Systematic review, meta-analysis and meta-regression analyses of double-blind randomised controlled trials. Journal of Psychopharmacology, 2021, 35, 910-918.	4.0	6

#	ARTICLE	IF	CITATIONS
91	Diversity of mechanism of action of psychotropic drugs in their anti-COVID-19 properties. <i>Molecular Psychiatry</i> , 2021, 26, 7093-7097.	7.9	6
92	Cost Reductions Associated With Long-Acting Injectable Antipsychotics According to Patient Age. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1061.	2.2	6
93	A neuroimaging study of emotion-cognition interaction in schizophrenia: the effect of ziprasidone treatment. <i>Psychopharmacology</i> , 2017, 234, 1045-1058.	3.1	5
94	Incidentaloma Discoveries in the Course of Neuroimaging Research. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 275-279.	0.5	5
95	Rapid screening for cognitive deficits in attention deficit and hyperactivity disorders with the screen for cognitive impairment in psychiatry. <i>ADHD Attention Deficit and Hyperactivity Disorders</i> , 2019, 11, 139-147.	1.7	5
96	Facing Confinement, the Comfort of WhatsApp Groups in Mental Health Communities. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 63-64.	1.9	5
97	Classical Koro and Koro-Like Symptoms: Illustration from Canada. <i>Journal of Psychosexual Health</i> , 2021, 3, 222-235.	0.6	5
98	Pattern of psychiatric in-patient admissions in Al Ain, United Arab Emirates. <i>BJPsych International</i> , 2021, 18, 46-50.	1.4	5
99	11.1 EFFECT OF INTERVAL TRAINING ON METABOLIC RISK FACTORS IN OVERWEIGHT INDIVIDUALS WITH PSYCHOSIS: A RANDOMIZED CONTROLLED TRIAL. <i>Schizophrenia Bulletin</i> , 2018, 44, S17-S17.	4.3	4
100	Sex, Age, Symptoms and Illness Duration and Their Relation with Gyrfication Index in Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2018, 12, 57-68.	1.4	4
101	Comparative effectiveness and safety of antipsychotic drugs in patients with schizophrenia initiating or reinitiating treatment: A Real-World Observational Study. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 456-468.	4.5	4
102	Long-term effect of prefrontal lobotomy on verbal fluency in patients with schizophrenia. <i>Brain and Cognition</i> , 2004, 55, 466-469.	1.8	3
103	About the nature of contextual impairments revealed by FN400 abnormalities in schizophrenia. <i>Frontiers in Human Neuroscience</i> , 2013, 7, 60.	2.0	3
104	Anandamide Is Involved in Appetite-Related Amygdala Hyperactivations in Schizophrenia Patients Treated With Olanzapine. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 82-83.	1.4	3
105	Measures of gluten-related reactivity in children with autism spectrum disorders in the absence of overt gastrointestinal symptoms: a pilot study from the United Arab Emirates. <i>Journal of International Medical Research</i> , 2020, 48, 030006052095265.	1.0	3
106	From QAAPAPLE 1 to QAAPAPLE 2: how do we move from one algorithm to another one with Long Acting Antipsychotics (LAIs). <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1325-1332.	2.8	3
107	Chronic Neuroleptic-Induced Parkinsonism Examined With Positron Emission Tomography. <i>Movement Disorders</i> , 2020, 35, 1189-1198.	3.9	3
108	Effectiveness of antipsychotics: is the CATIE trial a tsunami?. <i>Canadian Family Physician</i> , 2007, 53, 97-8.	0.4	3

#	ARTICLE	IF	CITATIONS
109	Impaired Coupling between the Dorsomedial Prefrontal Cortex and the Amygdala in Schizophrenia Smokers Viewing Anti-smoking Images. <i>Frontiers in Psychiatry</i> , 2017, 8, 109.	2.6	2
110	When should psychiatrists think of anti-NMDA receptor encephalitis? A systematic approach in clinical reasoning. <i>Asian Journal of Psychiatry</i> , 2021, 56, 102524.	2.0	2
111	Physician Characteristics Associated With Prescription of Long-Acting Injectable Antipsychotics. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1060.	2.2	2
112	More than just anti-NMDAR: the many facets of autoimmune encephalitis. <i>BJPsych Bulletin</i> , 2022, 46, 197-201.	1.1	2
113	Neural alterations of emotion processing in atypical trajectories of psychotic-like experiences. <i>NPJ Schizophrenia</i> , 2022, 8, .	3.6	2
114	Impact of early use of long-acting injectable antipsychotics on functional outcome in first episode psychosis: a 3-year longitudinal study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2023, 27, 25-34.	2.4	2
115	Markedly Reduced Thermal Pain Perception in a Schizoaffective Patient with Tardive Dyskinesia. <i>Case Reports in Psychiatry</i> , 2016, 2016, 1-3.	0.5	1
116	Use of long acting antipsychotics and relationship to newly diagnosed bipolar disorder: a pragmatic longitudinal study based on a Canadian health registry. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532095711.	2.7	1
117	The Roko Syndrome: A Mirror of Koro Syndrome. <i>Journal of Psychosexual Health</i> , 2021, 3, 88-91.	0.6	1
118	PrÃ©sentation. Histoire de la psychiatrie Ã l'UniversitÃ© de MontrÃ©al: passages et impasses. <i>Sante Mentale Au Quebec</i> , 0, 40, 11-33.	0.1	1
119	Urbanicity, Schizophrenia and Equitable Specialist Services Allocation. <i>Canadian Journal of Psychiatry</i> , 2021, , 070674372110406.	1.9	0
120	Inflammatory alterations in dual diagnosis patients with schizophrenia and substance use disorders. <i>FASEB Journal</i> , 2011, 25, .	0.5	0
121	The 10th Anniversary of the Eli Lilly Chair of Schizophrenia from the University of Montreal. <i>Canadian Journal of Psychiatry</i> , 2015, 60, S1-4.	1.9	0
122	Editorial: Novel Approaches to Improve Detection, Differentiation and Treatment in Mood Disorders. <i>Frontiers in Psychiatry</i> , 2022, 13, 837283.	2.6	0
123	COVID-19, Healthcare Workers and Mental Wellbeing: Lessons From One Very Cold and Another Very Hot Part of the World. <i>Canadian Journal of Psychiatry</i> , 2022, , 070674372210943.	1.9	0